
Cue Biopharma, Inc.: updates and filings
Price
$4.76
November 18, 2026Market cap $50M
What Ploutos Investor adds for Cue Biopharma
Part of Ploutos Investor, €9.99 a month
- The full history: 8 fiscal years, from 2018
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has fallen 66% since Nov 16, 2026, when the 10-Q these figures come from was filed ($14.10 then, $4.76 on Nov 18, 2026). The figures date from before that move.10-Q
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 16, 2026next Feb 12, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
August 2026
June 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 16, 2026Results of operationsForm8-K
- Nov 16, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 16, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Nov 10, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Oct 8, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Sep 21, 2026Regulation FD disclosure, other material eventsForm8-K
- Aug 21, 2026Over-5% holder statement (active)FormSCHEDULE 13D
- Aug 20, 2026FilingFormEFFECT
- Aug 18, 2026Correspondence with the SECFormCORRESP
- Aug 17, 2026Letter from the SECFormUPLOAD
- Aug 14, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 14, 2026Results of operationsForm8-K
- Aug 14, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 12, 2026Shelf registration for future offeringsFormS-3
- Aug 3, 2026Officer or director changeForm8-K
- Jul 22, 2026FilingFormD
- Jul 10, 2026Material agreement entered, unregistered sale of shares, officer or director change, other material eventsForm8-K
- Jul 1, 2026FilingFormEFFECT
- Jun 29, 2026Correspondence with the SECFormCORRESP
- Jun 25, 2026Letter from the SECFormUPLOAD
- Jun 18, 2026Shelf registration for future offeringsFormS-3
- Jun 17, 2026FilingFormEFFECT
- Jun 15, 2026Correspondence with the SECFormCORRESP
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 16, 2026 | 8-K | Results of operations | Document |
| Nov 16, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 16, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Nov 10, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Oct 8, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Sep 21, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Aug 21, 2026 | SCHEDULE 13D | Over-5% holder statement (active) | Document |
| Aug 20, 2026 | EFFECT | Filing | Document |
| Aug 18, 2026 | CORRESP | Correspondence with the SEC | Document |
| Aug 17, 2026 | UPLOAD | Letter from the SEC | Document |
| Aug 14, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 14, 2026 | 8-K | Results of operations | Document |
| Aug 14, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 12, 2026 | S-3 | Shelf registration for future offerings | Document |
| Aug 3, 2026 | 8-K | Officer or director change | Document |
| Jul 22, 2026 | D | Filing | Document |
| Jul 10, 2026 | 8-K | Material agreement entered, unregistered sale of shares, officer or director change, other material events | Document |
| Jul 1, 2026 | EFFECT | Filing | Document |
| Jun 29, 2026 | CORRESP | Correspondence with the SEC | Document |
| Jun 25, 2026 | UPLOAD | Letter from the SEC | Document |
| Jun 18, 2026 | S-3 | Shelf registration for future offerings | Document |
| Jun 17, 2026 | EFFECT | Filing | Document |
| Jun 15, 2026 | CORRESP | Correspondence with the SEC | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jun 19, 2015.
The full analysis
What do Cue Biopharma's filings show?
The filings are where every one of Cue Biopharma's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.